KR20150038752A - 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율 - Google Patents

조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율 Download PDF

Info

Publication number
KR20150038752A
KR20150038752A KR20157007810A KR20157007810A KR20150038752A KR 20150038752 A KR20150038752 A KR 20150038752A KR 20157007810 A KR20157007810 A KR 20157007810A KR 20157007810 A KR20157007810 A KR 20157007810A KR 20150038752 A KR20150038752 A KR 20150038752A
Authority
KR
South Korea
Prior art keywords
cytarabine
daunorubicin
patient
cpx
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157007810A
Other languages
English (en)
Korean (ko)
Inventor
아써 루이
크리스틴 스웬슨
로렌스 마이어
앤드류 자노프
Original Assignee
셀라토 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150038752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀라토 파마슈티칼즈, 인코포레이티드 filed Critical 셀라토 파마슈티칼즈, 인코포레이티드
Publication of KR20150038752A publication Critical patent/KR20150038752A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
KR20157007810A 2007-02-16 2008-02-15 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율 Ceased KR20150038752A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US60/901,772 2007-02-16
US96519607P 2007-08-17 2007-08-17
US60/965,196 2007-08-17
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097019393A Division KR20100014441A (ko) 2007-02-16 2008-02-15 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율

Publications (1)

Publication Number Publication Date
KR20150038752A true KR20150038752A (ko) 2015-04-08

Family

ID=39690832

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20157007810A Ceased KR20150038752A (ko) 2007-02-16 2008-02-15 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율
KR1020097019393A Ceased KR20100014441A (ko) 2007-02-16 2008-02-15 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097019393A Ceased KR20100014441A (ko) 2007-02-16 2008-02-15 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율

Country Status (20)

Country Link
US (2) US8092828B2 (enExample)
EP (3) EP3300601B1 (enExample)
JP (1) JP5314600B2 (enExample)
KR (2) KR20150038752A (enExample)
CN (1) CN105998046A (enExample)
AU (1) AU2008216083B2 (enExample)
CA (1) CA2678332C (enExample)
CY (1) CY1119631T1 (enExample)
DK (2) DK2120568T3 (enExample)
ES (2) ES2650167T3 (enExample)
FR (1) FR22C1034I2 (enExample)
HR (1) HRP20220428T3 (enExample)
HU (2) HUE058334T2 (enExample)
LU (1) LUC00271I2 (enExample)
NL (1) NL301185I2 (enExample)
NO (2) NO2120568T3 (enExample)
PL (2) PL2120568T3 (enExample)
PT (2) PT3300601T (enExample)
SI (1) SI3300601T1 (enExample)
WO (1) WO2008101214A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
CN104114156A (zh) * 2011-10-21 2014-10-22 切拉托尔制药公司 冻干脂质体
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6976941B2 (ja) * 2015-11-11 2021-12-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CN113164502A (zh) * 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
JP7580378B2 (ja) 2018-12-04 2024-11-11 デル－ヤン ティエン， 抗がん剤の送達のためのステレオコンプレックス
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
KR20050072790A (ko) * 2002-11-06 2005-07-12 셀진 코포레이션 골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
AU2005235455B2 (en) * 2004-04-22 2011-01-20 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF

Also Published As

Publication number Publication date
NO2022027I1 (no) 2022-06-30
DK3300601T3 (da) 2022-03-21
ES2650167T3 (es) 2018-01-17
FR22C1034I2 (fr) 2023-06-30
HUE058334T2 (hu) 2022-07-28
JP5314600B2 (ja) 2013-10-16
US20100303895A1 (en) 2010-12-02
HUS2200032I1 (hu) 2022-07-28
CN105998046A (zh) 2016-10-12
EP4046640A1 (en) 2022-08-24
WO2008101214A2 (en) 2008-08-21
FR22C1034I1 (fr) 2022-09-09
AU2008216083A1 (en) 2008-08-21
PT2120568T (pt) 2017-12-04
CA2678332C (en) 2015-06-02
EP2120568A2 (en) 2009-11-25
EP3300601A1 (en) 2018-04-04
WO2008101214A3 (en) 2008-11-20
EP3300601B1 (en) 2022-01-12
DK2120568T3 (en) 2017-12-11
EP2120568A4 (en) 2010-04-21
NL301185I2 (nl) 2022-07-21
AU2008216083A2 (en) 2009-09-24
SI3300601T1 (sl) 2022-05-31
PL3300601T3 (pl) 2022-05-02
KR20100014441A (ko) 2010-02-10
CY1119631T1 (el) 2018-04-04
PL2120568T3 (pl) 2018-03-30
HK1253378A1 (en) 2019-06-14
AU2008216083B2 (en) 2014-02-06
US8092828B2 (en) 2012-01-10
US20080199515A1 (en) 2008-08-21
HRP20220428T3 (hr) 2022-05-27
PT3300601T (pt) 2022-04-21
CA2678332A1 (en) 2008-08-21
NO2120568T3 (enExample) 2018-04-14
JP2010519224A (ja) 2010-06-03
LUC00271I2 (enExample) 2025-04-25
EP2120568B1 (en) 2017-11-15
ES2909903T3 (es) 2022-05-10

Similar Documents

Publication Publication Date Title
KR20150038752A (ko) 조혈암 및 증식성 질환의 치료를 위한 고정 약물 비율
US8431806B2 (en) Liposomal formulations of anthracycline agents and cytidine analogs
AU2006306108B2 (en) Fixed ratio drug combination treatments for solid tumors
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
US20090074848A1 (en) Combination formulations of cytidine analogs and platinum agents
CN101657098A (zh) 用于治疗造血性癌症和增殖性病症的固定药物比例
WO2022247921A1 (zh) 盐酸米托蒽醌脂质体用于制备治疗晚期实体瘤的药物的用途
HK40079853A (en) Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
JP2008514721A (ja) 治療方法
HK1253378B (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
Thomas et al. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia
HK1137294A (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
HK1137294B (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
HK40107529A (en) Antibody-conjugated liposome
Lerchenmüller et al. Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia
EP3664809A1 (en) Liposomal taxanes for treatment of sclc
CN101330917A (zh) 固定比率的联合用药治疗实体瘤

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2016101005061; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160829

Effective date: 20180306

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20180306

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2015 7007810

Appeal request date: 20160829

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016101005061

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2018201003925; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

St.27 status event code: A-3-3-V10-V12-crt-PJ2001

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PJ1302 Judgment (patent court)

St.27 status event code: A-3-3-V10-V15-crt-PJ1302

Decision date: 20181220

Decision identifier: 2018201003925

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 20165061 (2015 7007810)

Appeal request date: 20180504

Appellate body name: Patent Court

Decision text: 1. . 2. .

PJ2002 Appeal before the supreme court

St.27 status event code: A-3-3-V10-V12-crt-PJ2002

PJ1303 Judgment (supreme court)

St.27 status event code: A-3-3-V10-V15-crt-PJ1303

Decision date: 20190424

Decision authority category: Court of appeal

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2018 3925 (2015 7007810)

Appeal request date: 20190104

Appellate body name: Supreme Court

Decision identifier: 2019301010074

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000